A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Phase 2a Clinical Trial to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients
Latest Information Update: 28 Feb 2025
At a glance
- Drugs Vutiglabridin (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Glaceum
Most Recent Events
- 24 Feb 2025 Status changed from not yet recruiting to recruiting.
- 27 Mar 2024 New trial record